Thursday 7 May, 2026
Introduction: Dolutegravir (DTG) is a widely used integrase inhibitor for HIV treatment [1]. Despite its favorable pharmacokinetic profile, interindividual variability…
Read moreAbstracts
Mechanistic biomarker model of serum creatinine in critically ill patients
Thursday 7 May, 2026
Background Critically ill patients display pathophysiological features that significantly affect the pharmacokinetics of drugs. In particular, renal elimination processes exhibit…
Read moreThe relationship between pre-operative ipilimumab and nivolumab pharmacokinetics and treatment outcome in locoregionally advanced urothelial cancer
Thursday 7 May, 2026
Objectives: In the NABUCCO trial, patients with locoregionally advanced urothelial cancer (UC) received three cycles of pre-operative ipilimumab and nivolumab…
Read morePOPULATION PHARMACOKINETIC MODELLING TO SUPPORT BIOEQUIVALENCE ASSESSMENT OF GENERIC DRUGS: AN ILLUSTRATIVE SIMULATION STUDY USING AMODIAQUINE.
Thursday 7 May, 2026
Objectives: Bioequivalence (BE) of generic drugs is traditionally assessed using non-compartmental analysis (NCA) of exposure metrics such as AUC and…
Read moreIMPLEMENTING A FULL RANDOM EFFECTS MODEL (FREM) WORKFLOW IN R USING THE SAEMIX PACKAGE
Thursday 7 May, 2026
Background: Covariate analysis remains a critical challenge in pharmacometrics. The Full Random Effects Model (FREM) [1] offers a robust solution…
Read moreMIXED-EFFECTS MODELING OF THE PLASMA KINETICS OF THE ANTI-CD8 PET TRACER [18F]-2C8v144 AND THE NON-BINDING CONTROL TRACER [18F]-2C8V145 ENABLES ESTIMATES OF THE TOTAL AMOUNT OF CD8 IN THE BODY AND THE FRACTION PRESENT IN BLOOD, AND THE EQUILIBRIUM DISSOCIATION CONSTANT (K_D) OF [18F]-2C8v144; AND PREDICTIONS OF TOTAL BODY RECEPTOR OCCUPANCY BY [18F]-2C8v144
Thursday 7 May, 2026
Introduction: The success of checkpoint-inhibition immunotherapy in cancer patients hinges on the presence of CD8+ (“cytotoxic”) T cells in tumors,…
Read moreBEYOND EMPIRICAL BIOAVAILABILITY SCALING: A MECHANISTIC MODEL INCORPORATING PRE- AND POST-SYSTEMIC SATURABLE PROCESSES TO CHARACTERIZE NON-LINEAR PK OF ORALLY ADMINISTERED SMALL MOLECULES
Thursday 7 May, 2026
Introduction: Non-linear pharmacokinetics (PK) of orally administered small molecules is frequently addressed through empirical model adaptations such as dose-dependent bioavailability…
Read morePopulation Pharmacokinetic Modelling of AZD1705, a GalNAc-conjugated siRNA targeting ANGPTL3, in Participants with Dyslipidaemia
Thursday 7 May, 2026
Background AZD1705 is a N-acetylgalactosamine (GalNAc)–conjugated small interfering RNA (siRNA) targeting angiopoietin-like 3 (ANGPTL3), a regulator of lipoprotein metabolism [1]….
Read moreExperimental and Virus-Specific Drivers of EC50 Variability in Antiviral Assays Evaluated Using Mathematical Modeling
Thursday 7 May, 2026
Abstract Background: The half-maximal effective concentrations (EC50) reported for specific antiviral agents often vary widely across in vitro studies. The…
Read moreDevelopment and application of ML based drug renal clearance predictor
Thursday 7 May, 2026
Introduction: Renal clearance is one of determinants of systemic exposure for many small molecules and their metabolites. Robust estimation of…
Read more